Azzad Asset Management Inc /Adv Genmab A/S Transaction History

Azzad Asset Management Inc /Adv

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Apr 01, 2024	SELL	$27.94 - $35.44 $1.33 Million - $1.69 Million	-47,713 Closed	0 $0
Q4 2022 Apr 01, 2024	BUY	$33.8 - $47.06 $14,601 - $20,329	432 Added 0.91%	47,713 $2.02 Billion
Q1 2022 Apr 01, 2024	BUY	$30.95 - $39.68 $61 - $79	2 Added 0.0%	47,281 $1.71 Billion
Q4 2021 Apr 01, 2024	SELL	$35.87 - $47.12 $35 - $47	-1 Reduced -0.0%	47,279 $1.87 Billion
Q3 2021 Apr 01, 2024	BUY	$41.55 - $48.72 $124 - $146	3 Added 0.01%	47,280 $2.07 Billion
Q2 2021 Apr 01, 2024	SELL	$32.88 - $44.57 $131 - $178	-4 Reduced 0.01%	47,277 $1.93 Billion
Q1 2021 Apr 01, 2024	BUY	$30.92 - $44.4 $724,270 - $1.04 Million	23,424 Added 98.19%	47,281 $1.55 Billion
Q4 2020 Apr 01, 2024	BUY	$33.66 - $40.76 $803,026 - $972,411	23,857 New	23,857 $970 Million

248

61.3M

159K

38K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Azzad Asset Management Inc /Adv, based on Form 13F filings with the SEC.

Stay updated on Azzad Asset Management Inc /Adv with notifications on news.